2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)-Reference-Cited by-同舟云学术

2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)

Published:2024-02-15 Issue:7 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Skowronski Danuta M¹²,Zhan Yuping²,Kaweski Samantha E²,Sabaiduc Suzana²,Khalid Ayisha²,Olsha Romy³,Carazo Sara⁴,Dickinson James A⁵,Mather Richard G⁶³,Charest Hugues⁴,Jassem Agatha N²,Levade Inès⁴,Hasso Maan³,Zelyas Nathan⁷,Gao Ruimin⁸,Bastien Nathalie⁸

Affiliation:

1. University of British Columbia, Vancouver, Canada

2. British Columbia Centre for Disease Control, Vancouver, Canada

3. Public Health Ontario, Toronto, Canada

4. Institut National de Santé Publique du Québec, Québec, Canada

5. University of Calgary, Calgary, Canada

6. Queen’s University, Kingston, Canada

7. Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada

8. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada

Abstract

The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85).

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference33 articles.

1. Public Health Agency of Canada (PHAC). FluWatch report: January 7, 2023 to January 13, 2024 (week 2). Ottawa: PHAC; 2024. Available from: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/fluwatch/2023-2024/week-2-january-7-january-13-2024.html

2. National Influenza Annual Report, Canada, 2022-2023: Canada’s first fall epidemic since the 2019-2020 season.;Schmidt;Can Commun Dis Rep,2023

3. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials.;De Serres;Euro Surveill,2013

4. Government of Canada. COVID-19 vaccines: Canadian immunization guide. Ottawa: Government of Canada. [Accessed: 29 Jan 2024]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#t1

5. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season, Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focused ion beam-fabricated nanorod substrate for label-free surface-enhanced Raman spectroscopy and enabling dual virus detection;Talanta;2024-10

2. Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis;Infectious Diseases and Therapy;2024-09-10

3. Influenza vaccine effectiveness against influenza-associated hospitalizations in children, Hong Kong, November 2023 to June 2024;2024-08-30

4. Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom;Expert Review of Vaccines;2024-08-05

5. Effectiveness of influenza vaccine among the population in Chongqing, China, 2018–2022: A test negative design-based evaluation;Human Vaccines & Immunotherapeutics;2024-07-18